Karachi: BF Biosciences Limited has successfully reached full subscription for its initial public offering (IPO), demonstrating robust investor confidence. The subscription event, which occurred on October 2nd and 3rd, 2024, attracted applications for 6,325,000 ordinary shares, closely matching the issue size of 6,250,000 shares.

This public offering has generated significant interest across various investment categories, showcasing the strength and potential of BF Biosciences in the pharmaceutical sector. According to information available from the Pakistan Stock Exchange (PSX), the breakdown of applications revealed strong participation across all share categories. A total of 1,520 applications were received for the 500-share category totaling 760,000 shares, 644 applications for the 1,000-share category totaling 644,000 shares, and 238 applications for above 2,000 shares totaling 4,299,500 shares, contributing to a grand total of PKR 487.03 million.

The enthusiastic response underscores the market's positive reception to BF Biosciences' growth strategy and its commitment to advancing healthcare solutions. The IPO proceeds are earmarked for expanding production capacities and furthering research and development initiatives, poised to enhance the company's contributions to the pharmaceutical industry both domestically and internationally.

Subject to final scrutiny and approval, all applications for shares are expected to be allotted, paving the way for BF Biosciences' enhanced participation in Pakistan's vibrant stock market and its future growth trajectory.